|
gptkbp:instanceOf
|
beta blocker
antihypertensive drug
|
|
gptkbp:approvalYear
|
2007 (US)
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
C07AB12
|
|
gptkbp:brand
|
gptkb:Bystolic
Nebilet
|
|
gptkbp:CASNumber
|
99200-09-6
|
|
gptkbp:contraindication
|
severe bradycardia
cardiogenic shock
liver impairment
|
|
gptkbp:discoveredBy
|
gptkb:Janssen_Pharmaceutica
|
|
gptkbp:eliminationHalfLife
|
10 hours
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:hasMolecularFormula
|
C22H25F2NO4
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Nebivolol
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
beta-1 adrenergic receptor antagonist
nitric oxide-mediated vasodilation
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
dizziness
fatigue
headache
bradycardia
|
|
gptkbp:synonym
|
1-(6-fluoro-3,4-dihydro-2H-1-benzopyran-2-yl)-2-[(2-hydroxy-3-isopropylamino)propoxy]-3,4-dihydro-2H-1-benzopyran-2-ol
|
|
gptkbp:usedFor
|
heart failure
hypertension
|
|
gptkbp:bfsParent
|
gptkb:Beta_Blockers
|
|
gptkbp:bfsLayer
|
8
|